Originally published In Press as doi:10.1074/jbc.M001107200 on May 8, 2000
J. Biol. Chem., Vol. 275, Issue 29, 22442-22451, July 21, 2000
Surfactant Proteins A and D Bind CD14 by Different
Mechanisms*
Hitomi
Sano
§,
Hirofumi
Chiba
,
Daisuke
Iwaki
,
Hitoshi
Sohma
,
Dennis R.
Voelker¶, and
Yoshio
Kuroki
From the
Department of Biochemistry, Sapporo Medical
University School of Medicine, Sapporo, Japan and the
¶ Department of Medicine, National Jewish Medical and Research
Center, Denver, Colorado 80206
Received for publication, February 10, 2000, and in revised form, May 1, 2000
 |
ABSTRACT |
Surfactant proteins A (SP-A) and D (SP-D) are
lung collectins that are constituents of the innate immune system of
the lung. Recent evidence (Sano, H., Sohma, H., Muta, T., Nomura, S.,
Voelker, D. R., and Kuroki, Y. (1999) J. Immunol.
163, 387-395) demonstrates that SP-A modulates lipopolysaccharide
(LPS)-induced cellular responses by direct interaction with CD14. In
this report we examined the structural elements of the lung collectins
involved in CD14 recognition and the consequences for CD14/LPS
interaction. Rat SP-A and SP-D bound CD14 in a
concentration-dependent manner. Mannose and EDTA inhibited
SP-D binding to CD14 but did not decrease SP-A binding. The SP-A
binding to CD14 was completely blocked by a monoclonal antibody that
binds to the SP-A neck domain but only partially blocked by an antibody
that binds to the SP-A lectin domain. SP-A but not SP-D bound to
deglycosylated CD14. SP-D decreased CD14 binding to both smooth and
rough LPS, whereas SP-A enhanced CD14 binding to rough LPS and
inhibited binding to smooth LPS. SP-A also altered the migration
profile of LPS on a sucrose density gradient in the presence of CD14.
From these results, we conclude that 1) lung collectins bind CD14, 2)
the SP-A neck domain and SP-D lectin domain participate in CD14
binding, 3) SP-A recognizes a peptide component and SP-D recognizes a
carbohydrate moiety of CD14, and 4) lung collectins alter LPS/CD14 interactions.
 |
INTRODUCTION |
Pulmonary surfactant is a complex mixture of lipids and proteins
that functions to keep alveoli from collapsing at the end of expiration
(1). Surfactant proteins A
(SP-A)1 and D (SP-D) are
glycoprotein constituents of lung surfactant (2). SP-A and SP-D belong
to the collectin subgroup of the C-type lectin superfamily along with
mannose-binding proteins A and C, conglutinin, and CL43 (3). These
proteins possess similar characteristic structures consisting of a
short intersubunit disulfide forming the NH2 terminus
region, a collagen-like domain, a coiled-coil motif neck domain, and a
carbohydrate recognition domain (CRD) (2). The CRD region of SP-A is
essential for dipalmitoylphosphatidylcholine and galactosylceramide
binding, liposome aggregation, the inhibitory effect on lipid
secretion, and the augmentation of lipid uptake by alveolar type II
cells (4-11). Likewise, the CRD region of SP-D functions in the
recognition of the ligands phosphatidylinositol and glucosylceramide
(12, 13). In addition to their interaction with lipids and alveolar
type II cells, lung collectins interact with macrophages (14-16) and
enhance phagocytosis of a wide spectrum of microorganism (17-25). Lung
collectins are now thought to be important components of the innate
immune system of the lung (26-28).
Studies with transgenic mice provide strong support for a role of
pulmonary collectins in host defense properties. Mice homozygous for
null alleles of SP-A exhibit increased susceptibility to group B
streptococcal and Pseudomonas aeruginosa infections
(29-31). These mice clear the bacteria from the lungs at a slower rate than wild-type mice. Phagocytosis of P. aeruginosa by
alveolar macrophages in SP-A
/
mice is also
significantly decreased (30). Coadministration of SP-A with bacteria
into the airway of SP-A
/
mice enhance phagocytosis of
the bacteria by alveolar macrophages. Secretion of proinflammatory
cytokines into the alveolar space is significantly elevated in
SP-A
/
mice compared with SP-A+/+ mice after
intratracheal challenge with P. aeruginosa. These studies
suggest that SP-A modulates innate immune responses by several
different mechanisms. Although these in vivo studies
explicitly indicate that SP-A plays a crucial role in host defense of
the lung, the molecular basis of SP-A-mediated modification of
inflammatory responses remains to be elucidated.
Lipopolysaccharide (LPS), derived from Gram-negative bacteria, is a
potent stimulator of inflammation (32). Smooth LPS is composed of
O-antigen, core oligosaccharides, and lipid A, while rough
LPS lacks O-antigen and a part of the core oligosaccharides (33). The cellular responses to physiological amounts of LPS depend on
membrane CD14 that is phosphatidylinositol-anchored to the plasma
membrane of myeloid cells (34). A soluble form of CD14 which exists in
serum also facilitates the responsiveness of the cells to LPS (35, 36).
The principal role of CD14 is to bind LPS, but how CD14 acts in
transmitting LPS signal remains to be resolved. Recently, Toll-like
receptors have been implicated in signaling by LPS and CD14
(37-39).
SP-A and SP-D bind to rough LPS (24, 40). We have recently shown that
human SP-A and its collagenase-resistant fragment bind to lipid A and
rough LPS but not to smooth LPS (41). In addition, human SP-A interacts
directly with CD14, and modulates the LPS-induced cellular responses
(41). In the macrophage-like cell line U937 and alveolar macrophages,
SP-A inhibits expression and secretion of tumor necrosis factor
induced by smooth LPS. Preincubation of CD14 with SP-A prevents CD14
binding to smooth LPS. The disruption of smooth LPS-CD14 interaction by
SP-A may play an important role in reducing inflammatory responsiveness of the lung to smooth LPS. In contrast, the binding of CD14 to rough
LPS is significantly increased by the preincubation of CD14 with SP-A.
Moreover, the cellular response to rough LPS can be enhanced by SP-A.
From the results, we hypothesize that rough LPS, which is a ligand for
both CD14 and SP-A, might more effectively bind to the SP-A-CD14 complex.
The purpose of the current study was to extend our examination of lung
collectin interactions with LPS and CD14 by investigating: 1) the
interaction of SP-D with CD14, 2) the structural determinants that
participate in SP-D/CD14 recognition, and 3) the structural determinants involved in SP-A/CD14 interaction. These studies provide
clear evidence that SP-A and SP-D bind CD14 by different mechanisms and
alter LPS/CD14 interaction.
 |
EXPERIMENTAL PROCEDURES |
Reagents--
Rough LPS from Salmonella minnesota
Re595 was purchased from Sigma. 3H-Labeled LPS (587 cpm/ng)
from Escherichia coli K12 LCD25 (Rb) was obtained from List
Biological Laboratories Inc. (Cambell, CA).
Trans35S-labelTM was from ICN Pharmaceuticals
Inc. (Costa Mesa, CA).
Rat SP-A, SP-D, and Anti-SP-A Monoclonal
Antibodies--
Surfactant was isolated from lung lavage fluid of
Harlan Sprague-Dawley rats (7) that had been given an intratracheal
instillation of silica in saline 4 weeks before the lavage (42). The
surfactant was delipidated with 1-butanol. SP-A was isolated and
purified from the delipidated surfactant by mannose-Sepharose 6B column chromatography followed by gel filtration over Bio-Gel A-5m as described previously (43). SP-D was also purified from rat lung lavage
as described previously (44, 45).
For biotinylation, 150 µg of SP-A was incubated for 30 min at room
temperature in 0.5 ml of 0.1 M NaHCO3 buffer
(pH 8.3) containing N-hydroxysulfosuccinimidobiotin
(Sulfo-NHS-biotin) (Pierce) at a final concentration of 0.5 mg/ml. The
protein was then dialyzed against 5 mM Tris buffer (pH 7.4)
and stored at
20 °C.
Monoclonal antibodies 1D6 and 6E3 were prepared against rat SP-A as
described previously (46). The monoclonal antibodies recognize epitopes
in the polypeptide portion of SP-A and have nearly equivalent affinity
for the SP-A antigen. The epitopes for antibodies 1D6 and 6E3 have been
localized at the CRD and the neck domain, respectively (Fig.
1) (12).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 1.
Schematic representation of SP-A, SP-D,
SP-A/SP-D chimera ad5, and monoclonal antibody
epitopes. The domain structures of the monomeric subunit of rat
SP-A, SP-D, and chimera ad5 are shown. Domains that are
stippled are from SP-A and domains that are
unfilled are from SP-D. The black box indicates a
variant with an alternate amino terminus (72).
|
|
Recombinant SP-A, SP-D, and SP-A/SP-D Chimera--
The isolation
and sequencing of the 1.6-kilobase cDNA for rat SP-A was described
previously (47). The isolation of the 1.2-kilobase cDNA for rat
SP-D was also previously reported (48). The SP-A/SP-D chimera
ad5 containing the SP-A region
Asn1-Met134 and the SP-D region
Cys261-Phe355 was also constructed as described
previously (13). Fig. 1 shows a schematic representation of SP-A, SP-D,
and chimera ad5. Chimera ad5 exhibits defects of
binding dipalmitoylphosphatidylcholine and galactosylceramide and
interacting with alveolar type II cells but exhibits the
phosphatidylinositol and glucosylceramide binding property of SP-D
(13). The proteins were expressed in the baculovirus expression system
by the methods of O'Reilly et al. (49), using monolayers of
Spodoptera frugiperda cells and Trichoplusia ni (Tni) cells as described previously (13).
For labeling SP-A with Trans35S-label, the infected cells
were incubated in serum-free medium containing 500 µCi/ml
Trans35S-labelTM. After the incubation for 3 days, the medium was applied to a mannose-Sepharose column in the
presence of 2 mM CaCl2. The labeled protein was
eluted with 5 mM Tris buffer (pH 7.4) containing 2 mM EDTA. The specific activity of 35S-labeled
SP-A was approximately 25 cpm/ng. Electrophoretic analysis revealed
that the forms of 35S-labeled SP-A correlated well with the
forms of unlabeled protein.
Recombinant CD14 Expressed in Insect Cells--
The construction
of recombinant soluble CD14H in which the carboxyl end and the
glycosylphophatidylinositol-anchoring site of CD14 were replaced with a
protein kinase A site and a 6-histidine tag, was performed by a
modified method based on that described by Tapping and Tobias (50). The
expression of CD14H protein in the baculovirus expression system was
performed by the method (13) described above for recombinant
collectins. After incubation of Tni cells with recombinant
viruses for 3 days, the medium was collected after low-speed
centrifugation and dialyzed against 0.1 M Tris buffer (pH
8.0) containing 0.3 M NaCl. The dialyzed medium was
filtered and CD14H was purified by a column of nickel-nitrilotriacetic acid beads (Qiagen, Santa Clarita, CA) according to the manufacturer's instruction. The purified protein was finally dialyzed against 5 mM Tris buffer (pH 7.4) containing 0.15 M NaCl
and stored at
20 °C. Approximately 1 mg of CD14H protein was
obtained from 230 ml of medium.
Recombinant CD14 Expressed in CHO Cells--
The cDNA for
CD14H was also ligated into a pEE14 plasmid vector (51). The
recombinant CD14H was expressed in CHO cells using the glutamine
synthetase amplification system (51). The pEE14 vector containing CD14H
cDNA was transfected into CHO-K1 cells using LipofectAMINE (Life
Technologies, Inc.). Transfected cells were incubated in glutamine-free
Glasgow minimum essential medium supplemented with 10% dialyzed fetal
bovine serum (complete Glasgow minimum essential medium-10) in the
presence of 25 µM methionine sulfoximine (Sigma) for 2 weeks and resistant cell lines were cloned. A stable cell line that
secretes CD14H was obtained and maintained in the presence of 250 µM methionine sulfoximine. To produce soluble CD14H, the
cloned cells (0.5 × 106/100-mm dish) were incubated
in complete Glasgow minimum essential medium-10 for 4 days until
reaching 70% confluency and then changed to serum-free media
ExCell302 (JRH Biosciences). After 3-4 days incubation,
the medium was collected, dialyzed, and applied to a column of
nickel-nitrilotriacetic acid beads. The CD14H was then isolated as
described above. Approximately 1.5 mg of CD14H protein was obtained
from 200 ml of medium.
Analysis of SP-A, SP-D, and Recombinant CD14--
Protein
concentrations were estimated by the BCA assay (Pierce) using bovine
serum albumin (BSA) as a standard. Protein samples were separated by
SDS-polyacrylamide gel electrophoresis (13%) by the method of Laemmli
(52) and stained with Coomassie Brilliant Blue.
LPS Binding--
The binding of recombinant SP-A and SP-D to
Re-LPS was performed by the method described previously (41). The
protein binding to LPS was detected using anti-SP-A IgG or anti-SP-D
IgG and horseradish peroxidase (HRP)-labeled anti-rabbit IgG. The
peroxidase reaction was performed by using
o-phenylenediamine as a substrate and the absorbance was
measured at 492 nm.
35S-SP-A was used to determine the effect of monoclonal
antibodies on the binding of SP-A to LPS. 35S-SP-A (5 µg/ml) was preincubated at 37 °C for 1 h in the presence or
absence of 50 µg/ml monoclonal antibody 1D6 or 6E3 in 20 mM Tris buffer (pH 7.4) containing 0.15 M NaCl,
1 mg/ml BSA, and 5 mM CaCl2. The mixture of
SP-A and antibody (50 µl) was then incubated with Re-LPS coated onto
microtiter wells. After incubation for 5 h, the wells were washed,
and 100 µl of 0.1 N NaOH solution was added to the wells.
The suspended NaOH solution was transferred to vials and mixed with
scintillation liquid. The radioactivity of each vial was measured using
a
-radiation counter.
CD14 Binding--
The binding of SP-A and SP-D to CD14H coated
onto microtiter wells was performed by the method described previously
(41). The protein binding to the CD14 was detected using anti-SP-A IgG or anti-SP-D IgG and HRP-labeled anti-rabbit IgG. Anti-SP-D IgG was
used to detect chimera ad5 binding to CD14H since this
polyclonal antibody binds chimera ad5 strongly (13).
The ligand blot analysis was carried out by the method (41) described
previously with minor modifications. CD14H (1.5-4 µg) was
electrophoresed and transferred to PVDF membrane. The nonspecific
binding was blocked with 20 mM Tris buffer (pH 7.4) containing 0.15 M NaCl, 5 mM CaCl2,
5% (w/v) BSA, and 1% (w/v) polyvinylpyrrolidone (binding buffer). The
membrane was then incubated at room temperature overnight with 0.5-20
µg/ml native SP-A or SP-D in the binding buffer. The membranes were
then washed and incubated with anti-SP-A IgG or anti-SP-D IgG for 90 min, followed by the incubation with HRP-labeled anti-rabbit IgG
(1:1000) for 90 min. SP-A or SP-D that had bound to the PVDF membrane
was visualized by using chemiluminescence reagent (NEN Life Science
Products Inc.).
In some experiments 10 µg/ml biotinylated SP-A which had been
preincubated at room temperature for 2 h in the absence or
presence of monoclonal antibody 1D6 or 6E3, or control antibody 6B2
(100 µg/ml) was incubated with CD14H transferred onto the PVDF
membrane at room temperature overnight. The membrane was washed and
further incubated with HRP-conjugated streptavidin D (1:1000) for 20 min. After washing with phosphate-buffered saline containing 0.1%
(v/v) Triton X-100, the peroxidase reaction was performed by using
diaminobenzidine tetrahydrochloride as a substrate.
Enzyme Treatment of CD14--
For CD14 expressed in insect
cells, the protein (1.5 µg) was incubated with 1 unit of
N-glycosidase F (Roche Molecular Biochemicals) at 37 °C
for 2 h in 10 mM Tris buffer (pH 7.4) containing 10 mM EDTA, 2% (v/v)
-mercaptoethanol, 0.1% (w/v) SDS,
and 1% Nonidet P-40 (denaturing buffer). For CD14 expressed in CHO
cells, the protein (4 µg) was incubated with 1 unit of
N-glycosidase F (Roche Molecular Biochemicals), 10 units of
neuraminidase (Roche Molecular Biochemicals), and 1 milliunit of
O-glycosidase at 37 °C for 90 min in the denaturing
buffer described above.
Sucrose Density Gradient Centrifugation--
The 5-30% (w/v)
sucrose gradient was prepared by overlaying 0.25 ml of each step
varying by 2.5% sucrose concentration above a bottom cushion of 0.5 ml
of 40% sucrose. Forty ng of 3H-LPS was incubated in the
absence or presence of wild type rat SP-A (20 µg) and/or CD14H (20 µg) at 37 °C for 1 h in 200 µl of 20 mM Tris
buffer (pH 7.4) containing 0.15 M NaCl and 2 mM
CaCl2. Then 50 µl of 12.5% sucrose was added to each
incubated sample to adjust a final sucrose concentration at 2.5%, and
the samples were applied to the top of the gradient. The gradients were
centrifuged at room temperature at 30,000 rpm for 90 min by using RPS
56T rotor (Hitachi Koki Co., Tokyo, Japan). The fractions were
collected from the top of the gradient by careful vacuum aspiration.
The collected fractions were mixed with scintillation liquid, and the
radioactivity of each fraction was measured using a
-counter. Recovery of 3H-LPS ranged from 70 to 95% under all conditions.
 |
RESULTS |
Characterization of SP-A, SP-D, Chimera ad5, and CD14--
We have
previously characterized wild type SP-A, SP-D, and chimera
ad5 synthesized in insect cells using recombinant
baculoviruses (13, 53, 54). These proteins retain the properties of the authentic proteins in interacting with carbohydrates, phospholipids, glycosphingolipids, and alveolar type II cells (13, 53, 54). In this
study we used an invertebrate expression system to produce recombinant
SP-A and SP-D and CD14. Recombinant wild type SP-A (wt SP-A) and SP-D
(wt SP-D) were purified by affinity chromatography on mannose-Sepharose
6B. The cDNA for human CD14 was isolated from differentiated U937
cells and was engineered to replace the carboxyl end and the putative
glycosylphophatidylinositol anchoring site with a protein kinase A site
and a 6-histidine tag by the method described by Tapping and Tobias
(50). Recombinant CD14 (CD14H) was purified by affinity chromatography
on nickel-nitrilotriacetic acid beads. The purified proteins were
analyzed by SDS-polyacrylamide gel electrophoresis (Fig.
2). The wt SP-A migrated as a polymorphic band at approximately 30 kDa under reducing conditions. Recombinant SP-A produced in insect cells typically migrated faster than native SP-A derived from lung lavage due to different post-translational modifications as described previously (53). Chimera ad5
migrated as bands at 27-30 kDa as described previously (13). Native
and recombinant SP-Ds migrated as bands at approximately 40-43 kDa, as
described previously (13, 55). Purified CD14H produced by insect cells
migrated as bands at approximately 40-43 kDa, which is consistent with
the result described by Tapping and Tobias (50). All isoforms of SP-As,
SP-Ds, and CD14H on the gels were demonstrated to represent
immunoreactive proteins by immunoblotting analysis (data not shown).
Anti-rat SP-A monoclonal antibody 6E3 recognizes both wt SP-A and
chimera ad5 (13).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 2.
Electrophoretic analysis of SP-A, SP-D, and
CD14. Native rat SP-A (SP-A/nat), wild type recombinant SP-A
(SP-A/wt), SP-A/SP-D chimera (chimera ad5), native rat SP-D (SP-D/nat).
Wild type recombinant SP-D (SP-D/wt) and recombinant CD14 (CD14H)
produced by insect cells (3 µg/lane) were subjected to
SDS-polyacrylamide (13%) gel electrophoresis under reducing conditions
and visualized by Coomassie Brilliant Blue staining.
|
|
Properties of Collectin Binding to LPS--
Human SP-A binds to
rough LPS and causes calcium-induced aggregation of rough LPS (41).
Lectin blot analysis performed by Kuan et al. (24)
demonstrates that SP-D binds to Rc and Rd strains of rough LPS, and
they have described that the binding is inhibited by 100 mM
maltose or EDTA (24). Thus, we first examined whether EDTA and excess
mannose affect the binding of rat SP-A and SP-D to rough LPS. The wt
SP-A and wt SP-D bound to Re-LPS coated onto microtiter wells in the
presence of 5 mM CaCl2 (Fig.
3, A and B). When
20 µg/ml wt SP-A or SP-D was incubated with Re-LPS in the presence of
5 mM EDTA, the binding of the collectins to rough LPS was
negligible. The binding of SP-A and SP-D to rough LPS in the presence
of 0.2 M mannose was significantly reduced to 44-56% of
the levels of those without mannose. These results indicate that the
interaction of lung collectins with rough LPS depends on calcium, and
the lectin property of lung collectins takes part in the binding to
rough LPS.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 3.
The binding of lung collectins to rough
LPS. A and B, effect of EDTA and mannose.
Five µg of Re-LPS was coated onto microtiter wells and incubated with
20 µg/ml wt SP-A (A) or wt SP-D (B) at 37 °C
for 5 h in 20 mM Tris buffer (pH 7.4) containing 0.15 M NaCl, 1 mg/ml BSA, and 5 mM
CaCl2, where indicated (mannose), 0.2 M mannose
was also included. In some experiments 5 mM EDTA was added
instead of CaCl2(EDTA). The binding of SP-A to
LPS was detected by anti-SP-A or anti-SP-D IgG as described under
"Experimental Procedures." The data shown are mean ± S.E. of three
experiments. C, effect of anti-SP-A monoclonal antibodies.
35S-SP-A (5 µg/ml) was preincubated at 37 °C for
1 h in the presence or absence of antibody 1D6 or 6E3 (50 µg/ml), and the mixture of SP-A and antibody (50 µl) was incubated
with Re-LPS coated onto microtiter wells at 37 °C for 5 h. The
binding of 35S-SP-A to LPS was detected by measuring
radioactivity as described under "Experimental Procedures."
The results are expressed as % of the binding obtained by 35S-SP-A
alone. The mean value of 35S-SP-A bound to LPS in the
absence of the antibodies was 5 ng (100%). The data shown are mean ± S.E. of three experiments.
|
|
A previous study from this laboratory indicates that not only SP-A but
also the collagenase-resistant fragment of human SP-A bind to rough LPS
(41). These findings implicate the neck plus CRD domains in LPS
binding. In order to determine which domain of SP-A is involved in the
binding of SP-A to rough LPS, the effect of anti-SP-A monoclonal
antibodies on the binding of rough LPS was investigated. The epitopes
for anti-rat SP-A monoclonal antibodies 1D6 and 6E3 are located at the
CRD and the neck domain, respectively (Fig. 1) (12).
35S-Labeled SP-A was incubated with Re-LPS coated onto
microtiter wells in the absence or presence of antibody 1D6 or 6E3. The
binding of 35S-SP-A to LPS was determined by measuring
radioactivities associated with solid phase LPS. As shown in Fig.
3C, antibody 1D6 significantly inhibited the binding of
35S-labeled SP-A to Re-LPS. In contrast, preincubation of
35S-labeled SP-A with antibody 6E3 resulted in enhanced LPS
binding. These results clearly indicate that the CRD of SP-A is
involved in the binding of SP-A to rough LPS.
Binding of Rat Lung Collectins to CD14--
We have recently shown
that human SP-A binds CD14 (41). Since SP-D is homologous to SP-A, the
possibility that SP-D also binds CD14 was tested. We investigated the
binding of rat lung collectins to CD14 expressed in insect cells by
ligand blot and microtiter well binding. When CD14H was electrophoresed
and transferred to PVDF membrane, it was visualized as bands with
apparent molecular mass of 40-43 kDa by Coomassie Brilliant Blue
staining (Fig. 4A). For the
ligand blot analysis, the membrane was incubated with native rat SP-A,
SP-D, or BSA and probed with anti-SP-A or anti-SP-D IgG. SP-A or SP-D
that had bound to the membrane was detected as a band corresponding to
that of CD14H (Fig. 4A), demonstrating that lung collectins
bind to CD14. Furthermore, we examined the binding of the collectins to
CD14H coated onto microtiter wells. Both SP-A and SP-D bound to CD14H
in a concentration-dependent manner (Fig. 4B).
From these results, we conclude that lung collectins bind CD14
expressed in insect cells.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 4.
Rat lung collectins bind CD14.
A, ligand blot analysis of CD14H. Three µg of CD14H
produced by insect cells was electrophoresed and transferred to PVDF
membrane. CD14H on the membrane was visualized by Coomassie Brilliant
Blue staining (Coomassie stain). The membrane was also
incubated with rat SP-A, rat SP-D, or BSA and probed with anti-SP-A or
anti-SP-D IgG, followed by incubation with HRP-labeled anti-rabbit IgG
(ligand binding). B, concentration-dependent
binding of lung collectins to CD14H. Fifty-µl aliquots of 10 µg/ml
BSA ( , ) or CD14H ( , ) were coated onto microtiter wells
and incubated with the indicated concentrations of rat SP-A ( , )
and rat SP-D ( , ) at 37 °C overnight. The binding of
collectins to CD14H was detected using anti-SP-A or anti-SP-D IgG as
described under "Experimental Procedures." The data are mean ± S.E. of three experiments.
|
|
Properties of Collectin Binding to CD14--
sCD14 expressed using
the baculovirus/insect cell system has been shown to be active in
stimulating nonmyeloid cells in the presence of LPS (50, 56). We next
examined the binding of the collectins to CD14 in the presence of EDTA
or excess mannose, and compared it to the binding of those to rough
LPS. In the presence of Ca2+ wt SP-A bound to CD14H coated
onto microtiter wells (Fig.
5A). Inclusion of 1 mM EDTA instead of CaCl2 in the binding buffer failed to attenuate the binding of wt SP-A to CD14H. The SP-A binding
was enhanced rather than inhibited in the presence of 0.2 M
mannose. These results are quite different from the binding of SP-A to
rough LPS, and indicate that the interaction of SP-A with CD14 does not
require calcium and may be independent of the lectin property of
SP-A.

View larger version (9K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of EDTA and mannose on the binding of
SP-A, SP-D, and chimera ad5 to CD14. CD14H (10 µg/ml, 50 µl/well) produced by insect cells was coated onto
microtiter wells and incubated with 20 µg/ml wt SP-A (A),
wt SP-D (B), or chimera ad5 (C) at
37 °C overnight in 10 mM Hepes buffer (pH 7.4)
containing 0.15 M NaCl, 5 mg/ml BSA, and 5 mM
CaCl2 (Ca2+). The proteins binding
to CD14H were detected using polyclonal antibody as described under
"Experimental Procedures." One mM EDTA was also
included instead of CaCl2 (EDTA). In some
experiments the binding study was performed in the presence of 0.2 M mannose (mannose). The data shown are mean ± S.E. of
three experiments.
|
|
The wt SP-D bound to CD14H coated onto microtiter wells in the presence
of calcium (Fig. 5B). However, in contrast to the findings
with SP-A, the binding of wt SP-D to CD14H was prevented by 0.2 M mannose or 1 mM EDTA. The results clearly
indicate that the lectin property of SP-D is involved in SP-D-CD14
interaction. Chimera ad5 also bound to CD14H in the presence
of 5 mM CaCl2 and the binding was clearly
inhibited by the presence of EDTA or mannose (Fig. 5C). The
results demonstrate that chimera ad5 behaves like SP-D in
the binding to CD14H. These findings identify the CRD of SP-D as the
likely domain involved in CD14 recognition. The stark contrast in CD14
binding characteristics between SP-A and SP-D demonstrates that the
mechanisms of CD14 recognition must be different.
Effect of Anti-SP-A Monoclonal Antibodies on CD14
Binding--
Biotinylated SP-A was preincubated alone or with the
antibodies 1D6, 6E3, or control antibody 6B2, and the preincubated
samples were further incubated with a PVDF membrane containing
transblotted CD14. When biotinylated SP-A was incubated with the
membrane in the absence or the presence of antibody 6B2, the bands
corresponding to those of CD14 were clearly detected (Fig.
6), indicating that biotinylated SP-A
bound to CD14. The binding of biotinylated SP-A to CD14H was completely
inhibited by the preincubation of biotinylated SP-A with antibody 6E3.
Antibody 1D6 decreased, but did not completely inhibit the binding of
SP-A to CD14H. The results indicate that surface determinants within or
adjacent to the neck domain of SP-A are predominantly involved in the
interaction with CD14. The results are consistent with those described
in Fig. 5, demonstrating that EDTA and mannose do not inhibit SP-A/CD14
interactions.

View larger version (85K):
[in this window]
[in a new window]
|
Fig. 6.
Monoclonal antibody directed against the SP-A
neck blocks binding to CD14. CD14H (5 µg) produced by insect
cells was electrophoresed and transferred to PVDF membrane. The
membrane was incubated with 10 µg/ml biotinylated SP-A which had been
preincubated alone or with anti-SP-A monoclonal antibody 1D6, 6E3, or
control antibody 6B2 (100 µg/ml). The binding of biotinylated SP-A to
CD14H was detected by using HRP-conjugated streptavidin D as described
under "Experimental Procedures."
|
|
We further examined whether the SP-A neck domain present in wt SP-A or
chimera ad5 participates in the binding to CD14 using monoclonal antibody 6E3, which binds to chimera ad5 nearly
as well as wt SP-A (13). When wt SP-A bound to CD14H coated onto microtiter wells, it was readily detected by anti-SP-A polyclonal IgG
(Fig. 7A). However, antibody
6E3 essentially failed to detect the wt SP-A that bound to CD14H. This
finding is consistent with the idea that SP-A interacts with CD14 via
the neck domain. In contrast, antibody 6E3 effectively recognized
chimera ad5 that had bound to CD14H (Fig. 7B).
The absorbance obtained by using antibody 6E3 was almost comparable to
the level that was detected by anti-SP-D polyclonal IgG. This finding
indicates that SP-D type binding is dominant in the ad5
chimera. This conclusion is consistent with the finding that
ad5 behaves like SP-D upon interaction with CD14 (see Fig.
5). The results implicate the SP-D CRD region of
Cys261-Phe355 in the binding of SP-D to CD14.
Collectively, these results demonstrate that the neck domain is
involved in the binding of SP-A to CD14, and that the CRD is required
for the binding of SP-D to CD14.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 7.
Antibody 6E3 fails to detect wt SP-A but not
chimera ad5 bound to CD14. CD14H (10 µg/ml, 50 µl/well) produced by insect cells was coated onto microtiter wells
and incubated with wt SP-A or chimera ad5 at 37 °C
overnight as described under "Experimental Procedures."
A, the binding of wt SP-A to CD14H was detected by using
anti-SP-A IgG or anti-SP-A monoclonal antibody 6E3. B, the
binding of chimera ad5 to CD14H coated onto microtiter wells
was detected by using anti-SP-D IgG or antibody 6E3. The data shown are
mean ± S.E. of three experiments.
|
|
Binding of Lung Collectins to Deglycosylated Insect Cell-expressed
CD14--
Since CD14 possesses N-linked carbohydrate (57,
58), we next examined whether the carbohydrate moiety of CD14 is
required for the binding of the collectins. When CD14H (1.5 µg/lane)
was electrophoresed and stained with Coomassie Blue, it exhibited three
bands at 40-43 kDa with a main band of 41 kDa (Fig.
8, Coomassie stain/gel), which is in
agreement with the result described by Tapping and Tobias (50). The
N-glycosidase F-treated CD14H migrated as a band at 39 kDa.
Glycosylated and deglycosylated CD14H were electrophoresed and
transferred onto PVDF membrane and ligand blot analysis was performed
using native SP-A and SP-D. SP-A and SP-D were detected as bands
corresponding to those of control CD14H (Fig. 8, ligand
binding). SP-A appeared to bind untreated CD14H species of smaller
molecular size (40-41 kDa), whereas SP-D bound CD14H species of larger
molecular size (41-43 kDa). SP-A bound deglycosylated CD14 more
strongly than the untreated protein. Remarkably, SP-D exhibited almost
no binding to deglycosylated CD14.

View larger version (72K):
[in this window]
[in a new window]
|
Fig. 8.
Ligand blot analysis of
N-glycosidase F-treated CD14 reveals carbohydrate is
required for SP-D recognition. CD14H (1.5 µg) produced by insect
cells was treated with 1 unit of N-glycosidase F at 37 °C
for 2 h as described under "Experimental Procedures." The
proteins electrophoresed on the gel and those transferred on the PVDF
membranes were visualized by staining with Coomassie Brilliant Blue
(Coomassie stain). The PVDF membranes were also incubated
with SP-A (2 µg/ml) and SP-D (0.5 µg/ml) and the binding of SP-A
and SP-D to N-glycosidase F-treated and -untreated CD14H was
detected (ligand binding) using anti-SP-A and anti-SP-D IgG,
respectively, as described under "Experimental Procedures."
|
|
Binding of Lung Collectins to CD14 Expressed in Mammalian
Cells--
Proteins that are N-glycosylated in mammalian
cells are generally also glycosylated in insect cells. However, the
additional complex oligosaccharide synthesis does not appear to occur
in insect cells, although the pentasaccharide core common to
N-glycoproteins such as Man3GlcNAc2 is synthesized in insect
cells like in mammalian cells (49). In addition to N-linked
glycosylation, human sCD14 and recombinant sCD14 produced by CHO cells
contains O-linked glycosylation (59). Thus, we expressed
sCD14 in CHO cells and examined whether lung collectins bind mammalian
CD14. sCD14 produced by CHO cells (CHO CD14) migrated as broad bands
with 46-56 kDa when analyzed by electrophoresis under denaturing and
reducing conditions (Fig. 9A,
Coomassie stain). The predominant forms of CHO CD14 exhibited
molecular mass of 51-53 kDa. Ligand blot analysis revealed that both
SP-A and SP-D bound CHO CD14 (Fig. 9A, ligand binding). We
also performed the ligand binding using CHO CD14 treated with
N-glycosidase F, neuraminidase, and
O-glycosidase. The enzyme treatment resulted in the
reduction of molecular mass to 39 kDa (Fig. 9B, Coomassie
stain), which is in agreement with the results described by
Stelter et al. (59). The results obtained by ligand blot
analysis with the deglycosylated form of CHO CD14 are different between
the collectins. SP-A clearly bound deglycosylated CHO CD14. However,
SP-D failed to bind the deglycosylated form. The results obtained by
mammalian cell-expressed CD14 are consistent with those found with
insect cell-expressed CD14.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 9.
SP-D fails to recognize deglycosylated CD14
produced in mammalian cells. CD14H (4 µg) produced by CHO cells
(CHO CD14) was treated with N-glycosidase F, neuraminidase,
and O-glycosidase as described under "Experimental
Procedures." CHO CD14 (A) and deglycosylated CHO CD14
(B) electrophoresed on the gels were either stained with
Coomassie Brilliant Blue (Coomassie stain) or transferred
onto the PVDF membranes. The PVDF membranes were incubated with SP-A (5 µg/ml), SP-D (20 µg/ml), or BSA as a control, and the binding of
SP-A and SP-D to CHO CD14 was detected (ligand binding)
using anti-SP-A or anti-SP-D IgG, respectively, as described under
"Experimental Procedures."
|
|
Taken together, the data indicate that SP-A binds the peptide portion
of CD14 and that SP-D binds the carbohydrate moiety of CD14. The
results clearly demonstrate the different mechanisms utilized by the
lung collectins in recognition of CD14.
The Effect of Lung Collectins on LPS-CD14 Interaction--
A
recent study from this laboratory has shown that human SP-A decreased
the binding of CD14 to smooth LPS and increased the binding of CD14 to
rough LPS (41). The effect of rat SP-A and SP-D and chimera
ad5 on the binding of CD14H to solid phase smooth and rough
LPS was examined in this study. As with human SP-A, preincubation of wt
rat SP-A with CD14H inhibited binding to smooth LPS but increased the
CD14H binding to rough LPS (Fig. 10,
A and B). The wt SP-D and chimera ad5
attenuated the binding of CD14H to smooth LPS like wt SP-A (Fig.
10A). However, the preincubation of wt SP-D and chimera
ad5 with CD14 also decreased the binding of CD14H to rough
LPS (Fig. 10B). These results indicate that SP-A and SP-D
have distinct effects upon LPS-CD14 interaction.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 10.
SP-A and SP-D alter CD14 interactions with
rough and smooth LPS. CD14H (5 µg/ml) was preincubated alone
(control) or with wt SP-A, wt SP-D, or chimera
ad5 (50 µg/ml) at 37 °C for 1 h. The preincubated
mixtures were then incubated with smooth (A) or rough
(B) LPS coated onto microtiter wells, and the binding of
CD14H to LPS was detected by anti-CD14 polyclonal antibody. The results
are expressed as relative absorbance (%) compared with that obtained
from the binding of CD14H alone to LPS (100%). The absorbance at 492 nm obtained from the binding of CD14 to smooth or rough LPS was 0.236 or 0.176, respectively. The data are the average of two
experiments.
|
|
Because the recent (41) and present studies indicate that the binding
of CD14 to rough LPS is apparently enhanced by the preincubation of
CD14 with SP-A, we speculate that rough LPS can interact with an
SP-A-CD14 complex. In order to gain better insight into the interaction
of rough LPS with SP-A and CD14, sedimentation analysis of complex
mixtures of SP-A, CD14, and rough LPS was performed by using sucrose
density gradient centrifugation. We used 3H-labeled LPS
prepared from a rough strain of bacteria (Rb) which possesses somewhat
longer core oligosaccharides than Re-LPS. When 3H-LPS alone
was applied to the top of the gradient and centrifuged, 14% of the
total radioactivity was recovered at the bottom fraction (Fig.
11A), indicating the
aggregated form of 3H-LPS. After the preincubation of
3H-LPS with wt SP-A, 3H-LPS migrated a short
distance into the gradient and was recovered mainly in fraction 3 (Fig.
11B). A similar profile of the migration of
3H-LPS was observed upon incubation with CD14H (Fig.
11C). In contrast, when 3H-LPS was preincubated
in the presence of both wt SP-A and CD14H, a significant amount of
3H-LPS remained at the top of the gradient (Fig.
11D). As much as 16% of total radioactivity was detected at
the top of the gradient, while only 4.5, 5, or 6% of that was
recovered from 3H-LPS alone, 3H-LPS plus SP-A
or 3H-LPS plus CD14H, respectively. Taken together, these
results show that inclusion of SP-A in the solution containing CD14H
and rough LPS altered the migration profile of LPS. This may be
explained by assuming that SP-A can simultaneously interact with CD14
and rough LPS. Collectively, these results demonstrate that lung
collectins can alter LPS-CD14 interaction.

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 11.
Distribution of 3H-LPS analyzed
by sucrose density gradient centrifugation. 3H-LPS (40 ng) was incubated alone (A), with 20 µg of SP-A
(B), with 20 µg of CD14H (C), or with both SP-A
and CD14H (D) at 37 °C for 1 h before application to
a 5-30% sucrose density gradient centrifugation as described under
"Experimental Procedures." The radioactivity in each fraction is
presented as % of total recovered radioactivity. The arrow
indicates the fraction containing the maximum radioactivity. The data
shown are a representative one of three experiments.
|
|
 |
DISCUSSION |
This study demonstrates that the lung collectins, SP-A and SP-D,
bind CD14 by different mechanisms. The structure required for the
binding of SP-A to rough LPS is distinct from that for CD14 binding.
SP-A interacts with CD14 and rough LPS via the neck domain and the CRD,
respectively. In contrast, SP-D interacts with CD14 and rough LPS via
the CRD. This work also demonstrates that the structure of CD14
required for SP-A binding is different from that for SP-D binding. SP-A
binds the peptide portion of CD14 but SP-D binds its carbohydrate moiety.
The CRDs of lung collectins appear to be the principal protein domains
involved in binding to rough LPS in this study. The requirement for
calcium and the lectin property also support the role of CRD in LPS
binding. The present results are consistent with the study by Kuan
et al. (24) demonstrating that the binding of SP-D to rough
strain bacteria was inhibited by the presence of EDTA or maltose. The
interaction with rough LPS may also be one of the important
physiological functions of the CRD of the lung collectins.
In contrast to the association with rough LPS, the interaction of SP-A
with CD14 does not require calcium and is not attenuated in the
presence of mannose. Since antibody 6E3 completely inhibited binding of
SP-A to CD14 and antibody 6E3 failed to recognize the SP-A that had
bound to CD14, the neck domain of SP-A is likely to be directly
involved in CD14 binding. Since antibody 6E3 inhibits surfactant lipid
uptake by type II cells, the neck domain also plays some role in lipid
recognition (12). A previous study using SP-A/SP-D chimeric proteins
also suggest that the neck region may account for some but not all of
the lipid binding properties of SP-A (55). In addition, the mutants in
which the regions in the neck domain of SP-A are deleted fail to bind
to the mannose-Sepharose column (12), indicating that the neck domain
might be important for the folding of SP-A. The present study
demonstrating that SP-A interacts with CD14 via the neck domain may
imply a novel function of the SP-A neck domain in protein-protein interactions.
However, the neck domain of SP-A in chimera ad5 does not
seem to be sufficient for interacting with CD14. The ad5
chimera binds CD14 via the SP-D CRD but not via the SP-A neck domain, since anti-SP-A monoclonal antibody 6E3 can effectively detect the
chimera ad5 that is bound to CD14H. In contrast, the 6E3
epitope becomes unavailable when wt SP-A binds CD14H. EDTA and excess monosaccharide alter the binding of the chimera to CD14H, providing further evidence that the CRD of SP-D is the major site for binding. Although the role of the SP-A neck domain in the chimera ad5
molecule is unclear, the substitution of the SP-D region
Cys261-Phe355 for the corresponding SP-A region
may alter the structure and the function of the SP-A neck domain.
The neck domain of SP-A contains both an amphipathic helix and a
segment of hydrophobic amino acids (60). In contrast, SP-D lacks such a
clearly identifiable hydrophobic region (61). The structural
differences between SP-A and SP-D probably account for the differences
in interacting with CD14. CD14 contains 10 leucine-rich repeat motifs
(LXXLXLX) (62). In addition, the NH2-terminal 152 amino acids of CD14 are sufficient to bind
LPS (63). Furthermore, the region including amino acids 57 to 64 has
been recently suggested to be involved in LPS binding (64, 65). The
SP-A neck domain with amphipathic and hydrophobic regions may interact
with the hydrophobic leucine-rich region of CD14.
We have recently demonstrated that SP-A modulates the LPS-induced
cellular response in a macrophage-like cell line and alveolar macrophages (41). SP-A can inhibit smooth LPS-induced tumor necrosis
factor
expression by alveolar macrophages. We have proposed that
the binding of SP-A to CD14 prevents the interaction of CD14 with
smooth LPS. In contrast, rough LPS-induced tumor necrosis factor
expression is increased by preincubation of alveolar macrophages with
SP-A. The binding of CD14 to rough LPS is modestly enhanced by SP-A.
Rough LPS, which is a ligand for both CD14 and SP-A, appears to more
efficiently associate with an SP-A-CD14 complex. The present study
strongly supports this idea, since SP-A interacts with rough LPS via
its CRD and with CD14 via its neck domain. The distinct structural
domain topology of SP-A binding to rough LPS and CD14 may enable the
protein to interact simultaneously with both ligands.
Analysis by sucrose density gradient centrifugation revealed that the
sedimentation of 3H-LPS was markedly altered in the
presence of SP-A or CD14. One interpretation of this finding is that
3H-LPS may partially disaggregate in the presence of SP-A
or CD14. Incubation of 3H-LPS with both SP-A and CD14
changes the distribution of 3H-LPS more dramatically. This
migration is quite different from that induced by SP-A or CD14 alone.
The SP-A function of dispersing LPS aggregates may be similar to the
function described for LPS-binding protein which enables a
3H-LPS·35S-sCD14 complex to form (66, 67).
This study clearly indicates that the physical form of rough LPS in the
presence of CD14 can be significantly modified by the addition of SP-A.
Collectively, these results support the idea of a ternary complex of
SP-A, CD14, and rough LPS.
The ternary interaction of SP-A with CD14 and rough LPS suggests one of
the important roles of SP-A in the host defense mechanism of the lung.
By associating with rough LPS or dispersing rough LPS aggregates, SP-A
may facilitate CD14 interactions with LPS and initiate physiological
responses against pathogens. The present results also demonstrate that
SP-D inhibits the binding of CD14 to smooth and rough LPS. In contrast,
SP-A enhances the binding of CD14 to rough LPS but inhibits the binding
to smooth LPS. Thus, this study indicates that SP-D and SP-A act
differently on LPS-CD14 interaction. Since the association of LPS with
CD14 also plays an important role in LPS clearance (68), these findings
are consistent with other studies demonstrating that SP-A but not SP-D
enhanced phagocytosis of rough LPS-containing bacteria by alveolar
macrophages (69). Since most Gram-negative bacteria colonizing the
respiratory tract express rough LPS (70), the increased association of
CD14 with rough LPS induced by SP-A may be important to initiate the
immune response. However, the interaction of CD14 with LPS also results
in the release of numerous inflammatory mediators which can have marked
pathological effects on the lung without adequate regulation. SP-D may
act as a negative regulator to protect against a chronic inflammatory
state. The role of SP-D in modulating LPS-elicited cellular responses
is now under investigation.
The characteristics of mice harboring null alleles for SP-A provide
strong in vivo evidence that the collectins are important components of the innate immune system of the lung (29-31). In one
recent report (71) production of tumor necrosis factor
and nitric
oxide in SP-A
/
mice has been shown to significantly
increase after intratracheal administration of smooth LPS when compared
with wild type mice. Intratracheal administration of SP-A to
SP-A
/
mice restored the production of proinflammatory
cytokines to that of SP-A+/+ mice. The study demonstrates
that endogenous and exogenous SP-A inhibit LPS-induced cytokine
production in vivo. Earlier in vitro studies (41)
also demonstrate that SP-A decreases the binding of smooth LPS to CD14
and markedly attenuates inflammatory cellular responses. Taken
together, these in vivo and in vitro studies are
consistent with the idea that SP-A interacts directly with immune cells
to modulate LPS-induced cellular responses, suggesting an
anti-inflammatory role of SP-A. The present study provides the
molecular and mechanistic details by which lung collectins can modulate
the innate immune response to LPS in the lung.
In conclusion, this study provides clear evidence that SP-A and SP-D
bind CD14. The neck region of SP-A and the CRD region of SP-D are
involved in CD14 recognition. SP-A binding to CD14 enhances rough LPS
binding but inhibits smooth LPS binding. SP-D binding to CD14 inhibits
smooth and rough LPS binding. The lung collectin-CD14 interactions are
likely to play a critical role in modulating the inflammatory response
of the lungs to specific pathogens.
 |
ACKNOWLEDGEMENT |
We thank Dr. Toyoaki Akino (Sapporo Medical
University) for valuable comments and encouragement.
 |
FOOTNOTES |
*
This work was supported in part by grant-in-aid (to H. S. and Y. K.) for Scientific Research from the Ministry of
Education, Science, Sports and Culture, Japan, and National Institutes
of Health Grant HL 45286 (to D. R. V.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address; Dept. of Pediatrics, Saitama Medical Center,
Saitama Medical School, Kawagoe 350-8550, Japan.
To whom correspondence should be addressed: Dept. of
Biochemistry, Sapporo Medical University School of Medicine, South-1 West-17, Chuo-ku, Sapporo 060-8556, Japan. Tel.: 81-11-611-2111; Fax:
81-11-611-2236; E-mail: kurokiy@sapmed.ac.jp.
Published, JBC Papers in Press, May 8, 2000, DOI 10.1074/jbc.M001107200
 |
ABBREVIATIONS |
The abbreviations used are:
SP-A, surfactant
protein A;
SP-D, surfactant protein D;
CRD, carbohydrate-recognition
domain;
LPS, lipopolysaccharide;
BSA, bovine serum albumin;
HRP, horseradish peroxidase;
PVDF, polyvinylidene difluoride.
 |
REFERENCES |
| 1.
|
King, R. J.,
and Clements, J. A.
(1972)
Am. J. Physiol.
223,
707-714
|
| 2.
|
Kuroki, Y.,
and Voelker, D. R.
(1994)
J. Biol. Chem.
269,
25943-25946
|
| 3.
|
Day, A. J.
(1994)
Biochem. Soc. Trans.
22,
83-88
|
| 4.
|
Kuroki, Y.,
and Akino, T.
(1991)
J. Biol. Chem.
266,
3068-3073
|
| 5.
|
Kuroki, Y.,
Gasa, S.,
Ogasawara, Y.,
Makita, A.,
and Akino, T.
(1992)
Arch. Biochem. Biophys.
299,
261-267
|
| 6.
|
Childs, R. A.,
Wright, J. R.,
Ross, G. F.,
Yuen, C.-T.,
Lawson, A. M.,
Chai, W.,
Drickamer, K.,
and Feizi, T.
(1992)
J. Biol. Chem.
267,
9972-9979
|
| 7.
|
Hawgood, S.,
Benson, B.,
and Hamilton, R. J.
(1985)
Biochemistry
24,
184-190
|
| 8.
|
Dobbs, L. G.,
Wright, J. R.,
Hawgood, S.,
Gonzalez, R.,
Venstrom, K.,
and Nellenbogen, J.
(1987)
Proc. Natl. Acad. Sci. U. S. A.
84,
1010-1014
|
| 9.
|
Rice, W.,
Ross, G. F.,
Singleton, F. M.,
Dingle, S.,
and Whitsett, J. A.
(1987)
J. Appl. Physiol.
63,
692-698
|
| 10.
|
Wright, J. R.,
Wager, R. E.,
Hawgood, S.,
Dobbs, L.,
and Clements, J. A.
(1987)
J. Biol. Chem.
262,
2888-2894
|
| 11.
|
Horowitz, A. D.,
Moussavian, B.,
and Whitsett, J. A.
(1996)
Am. J. Physiol.
270,
L69-L79
|
| 12.
|
Kuroki, Y.,
McCormack, F. X.,
Ogasawara, Y.,
Mason, R. J.,
and Voelker, D. R.
(1994)
J. Biol. Chem.
269,
29793-29800
|
| 13.
|
Sano, H.,
Kuroki, Y.,
Honma, T.,
Ogasawara, Y.,
Sohma, H.,
Voelker, D. R.,
and Akino, T.
(1998)
J. Biol. Chem.
273,
4783-4789
|
| 14.
|
Pison, U.,
Wright, J. R.,
and Hawgood, S.
(1992)
Am. J. Physiol.
262,
L412-L417
|
| 15.
|
Miyamura, K.,
Leigh, L. E. A.,
Lu, J.,
Hopkin, J.,
Lopez Bernal, A.,
and Reid, K. B. M.
(1994)
Biochem. J.
300,
237-242
|
| 16.
|
Kuan, S. F.,
Persson, A.,
Parghi, D.,
and Crouch, E.
(1994)
Am. J. Respir. Cell Mol. Biol.
10,
430-436
|
| 17.
|
van Iwaarden, F.,
Welmers, B.,
Verhoef, J.,
Haagsman, H. P.,
and van Golde, L. M. G.
(1990)
Am. J. Respir. Cell Mol. Biol.
2,
91-98
|
| 18.
|
Greertsma, M. F.,
Nibbering, P. H.,
Haagsman, H. P.,
Daha, M. R.,
and Van Furth, R.
(1994)
Am. J. Physiol.
267,
L578-L584
|
| 19.
|
Van Iwaarden, J. F.,
van Strijp, J. A. G.,
Visser, H.,
Haagsman, H. P.,
Verhoef, J.,
and van Golde, L. M. G.
(1992)
J. Biol. Chem.
267,
25039-25043
|
| 20.
|
McNeely, T. B.,
and Coonrod, J. D.
(1994)
Am. J. Respir. Cell. Mol. Biol.
11,
114-122
|
| 21.
|
Gaynor, C. D.,
McCormack, F. X.,
Voelker, D. R.,
McGowan, S. E.,
and Schlesinger, L. S.
(1995)
J. Immunol.
155,
5343-5351
|
| 22.
|
Kabha, K.,
Schmegner, J.,
Keisari, Y.,
Parolis, H.,
Schlepper-Schaefer, J.,
and Ofek, I.
(1997)
Am. J. Physiol.
272,
L344-L352
|
| 23.
|
Hartshorn, K. L.,
Crouch, E. C.,
White, M. R.,
Eggleton, P.,
Tauber, A. I.,
Chang, D.,
and Sastry, K.
(1994)
J. Clin. Invest.
94,
311-319
|
| 24.
|
Kuan, S.-F.,
Rust, K.,
and Crouch, E.
(1992)
J. Clin. Invest.
90,
97-106
|
| 25.
|
O'Riordan, D. M.,
Standing, J. E.,
Kwon, K.-Y.,
Chang, D.,
and Crouch, E. C.
(1995)
J. Clin. Invest.
95,
2699-2710
|
| 26.
|
Wright, J. R.
(1997)
Physiol. Rev.
77,
931-962
|
| 27.
|
Crouch, E. C.
(1998)
Am. J. Respir. Cell Mol. Biol.
19,
177-201
|
| 28.
|
Mason, R. J.,
Greene, K.,
and Voelker, D. R.
(1998)
Am. J. Physiol.
275,
L1-L13
|
| 29.
|
LeVine, A. M.,
Bruno, M. D.,
Huelsman, K. M.,
Ross, G. F.,
Whitsett, J. A.,
and Korfhagen, T. R.
(1997)
J. Immunol.
158,
4336-4340
|
| 30.
|
LeVine, A. M.,
Kurak, K. E.,
Bruno, M. D.,
Stark, J. M.,
Whitsett, J. A.,
and Korfhagen, T. M.
(1998)
Am. J. Respir. Cell Mol. Biol.
19,
700-708
|
| 31.
|
LeVine, A. M.,
Kurak, K. E.,
Wright, J. R.,
Watford, W. T.,
Bruno, M. D.,
Ross, G. F.,
Whitsett, J. A.,
and Korfhagen, T. R.
(1999)
Am. J. Respir. Cell Mol. Biol.
20,
279-286
|
| 32.
|
Ulevitch, R. J.,
and Tobias, P. S.
(1995)
Annu. Rev. Immunol.
13,
437-457
|
| 33.
|
Hancock, R. E. W.,
Karunaratne, K.,
and Bernegger-Egli, C.
(1994)
in
Molecular Organization and Structual Role of Outer Membrane Macromolecules: New Comprehensive Biochemistry, Bacterial Cell Wall
(Ghuysen, J. M.
, and Hakenbeck, R., eds), Vol. 27
, pp. 263-276, Elsevier Science B. V., AmsterdamChapter 12
|
| 34.
|
Wright, S. D.,
Ramos, R. A.,
Tobias, P. S.,
Ulevitch, R. J.,
and Mathison, J. C.
(1990)
Science
21,
1431-1433
|
| 35.
|
Hailman, E.,
Vasselon, T.,
Kelly, M.,
Busse, L. A.,
Hu, M. C. T., S., L. H.,
Detmers, P. A.,
and Wright, S. D.
(1996)
J. Immunol.
156,
4384-4390
|
| 36.
|
Frey, E. A.,
Miller, D. S.,
Jahr, T. G.,
Sundan, A.,
Brazil, V.,
Espevik, T.,
Finlay, B. B.,
and Wright, S. D.
(1992)
J. Exp. Med.
176,
1665-1671
|
| 37.
|
Yang, R. B.,
Mark, M. R.,
Gray, A.,
Huang, A.,
Hong Xie, M.,
Zhang, M.,
Goddard, A.,
Wood, W. I.,
Gurney, A. L.,
and Godowski, P. J.
(1998)
Nature
395,
284-288
|
| 38.
|
Kirschning, C. J.,
Wesche, H.,
Ayres, T. M.,
and Rothe, M.
(1998)
J. Exp. Med.
188,
2091-2097
|
| 39.
|
Poltorak, A.,
Xiaolong, H.,
Smirnova, I.,
Liu, M.-Y.,
Van Huffel, C.,
Du, X.,
Birdwell, D.,
Alejos, E.,
Silva, M.,
Galanos, C.,
Freudenberg, M.,
Ricciardi-Castagnoli, P.,
Layton, B.,
and Beutler, B.
(1998)
Science
282,
2085-2088
|
| 40.
|
Van Iwaarden, J. F.,
Pikaar, J. C.,
Storm, J.,
Brouwer, E.,
Verhoef, J.,
Oosting, R. S.,
Van Golde, L. M. G.,
and Van Strip, J. A. G.
(1994)
Biochem. J.
303,
407-411
|
| 41.
|
Sano, H.,
Sohma, H.,
Muta, T.,
Nomura, S.,
Voelker, D. R.,
and Kuroki, Y.
(1999)
J. Immunol.
163,
387-395
|
| 42.
|
Dethloff, L. A.,
Gilmore, L. B.,
Brody, A. R.,
and Hook, G. E. R.
(1986)
Biochem. J.
233,
111-118
|
| 43.
|
Kuroki, Y.,
Mason, R. J.,
and Voelker, D. R.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
5566-5570
|
| 44.
|
Kuroki, Y.,
Shiratori, M.,
Murata, Y.,
and Akino, T.
(1991)
Biochem. J.
279,
115-119
|
| 45.
|
Ogasawara, Y.,
Kuroki, Y.,
and Akino, T.
(1992)
J. Biol. Chem.
267,
21244-21249
|
| 46.
|
Kuroki, Y.,
Mason, R. J.,
and Voelker, D. R.
(1988)
J. Biol. Chem.
263,
3388-3394
|
| 47.
|
Sano, K.,
Fisher, J.,
Mason, R. J.,
Kuroki, Y.,
Schilling, J.,
Benson, B.,
and Voelker, D. R.
(1987)
Biochem. Biophys. Res. Commun.
144,
367-374
|
| 48.
|
Shimizu, H.,
Fisher, J. H.,
Papst, P.,
Benson, B.,
Lau, K.,
Mason, R. J.,
and Voelker, D. R.
(1992)
J. Biol. Chem.
267,
1853-1857
|
| 49.
|
O'Reilly, D. R.,
Miller, L. K.,
and Luckow, V. A.
(1992)
Baculovirus Expression Vector, A Laboratory Manual
, W. H. Freeman and Co., New York
|
| 50.
|
Tapping, R. I.,
and Tobias, P. S.
(1997)
J. Biol. Chem.
272,
23157-23164
|
| 51.
|
Ausbel, F. M.,
Brent, R.,
Kingston, R. E.,
Moore, D. D.,
Seidman, L. G.,
Smith, J. A.,
and Struhl, K.
(1992)
Current Protocols in Molecular Biology
, John Wiley & Sons, Inc., New York
|
| 52.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685
|
| 53.
|
McCormack, F. X.,
Calvet, H. M.,
Watson, P. A.,
Smith, D. L.,
Mason, R. J.,
and Voelker, D. R.
(1994)
J. Biol. Chem.
269,
5833-5841
|
| 54.
|
Honma, T.,
Kuroki, Y.,
Tsunezawa, W.,
Ogasawara, Y.,
Sohma, H.,
Voelker, D. R.,
and Akino, T.
(1997)
Biochemistry
36,
7176-7184
|
| 55.
|
Ogasawara, Y.,
McCormack, F. X.,
Mason, R. J.,
and Voelker, D. R.
(1994)
J. Biol. Chem.
269,
29785-29792
|
| 56.
|
Haziot, A.,
Rong, G. W.,
Brazil, V.,
Silver, J.,
and Goyert, S. M.
(1994)
J. Immunol.
152,
5868-5876
|
| 57.
|
Bazil, V.,
Horejsi, V.,
Baudys, M.,
Kristofova, H.,
Strominger, J. L.,
Kostka, W.,
and Hilgert, I.
(1986)
Eur. J. Immunol.
16,
1583-1589
|
| 58.
|
Simmons, D. L.,
Tan, S.,
Tenen, D. G.,
Nicholson-Weller, A.,
and Seed, B.
(1989)
Blood
73,
284-289
|
| 59.
|
Stelter, F.,
Pfister, M.,
Bernheiden, M.,
Jack, R. S.,
Bufler, P.,
Engelmann, H.,
and Schütt, C.
(1996)
Eur. J. Biochem.
236,
457-464
|
| 60.
|
Ross, G. F.,
Notter, R. H.,
Meuth, J.,
and Whitsett, J. A.
(1986)
J. Biol. Chem.
261,
14283-14291
|
| 61.
|
Rust, K.,
Grosso, L.,
Zhang, V.,
Chang, D.,
Persson, A.,
Longmore, W.,
Cai, G.-Z.,
and Crouch, E.
(1991)
Arch. Biochem. Biophys.
290,
116-126
|
| 62.
|
Ferrero, E.,
Hsieh, C. L.,
Francke, U.,
and Goyert, S. M.
(1990)
J. Immunol.
145,
331-336
|
| 63.
|
Juan, T. S.,
Kelley, M. J.,
Johnson, D. A.,
Busse, L. A.,
Hailman, E.,
Wright, S. D.,
and Lichenstein, H. S.
(1995)
J. Biol. Chem.
270,
1382-1387
|
| 64.
|
McGinley, M. D.,
Narhi, L. O.,
Kelley, M. J.,
Davy, E.,
Robinson, J.,
Rohde, M. F.,
Wright, S. D.,
and Lichenstein, H. S.
(1995)
J. Biol. Chem.
270,
5213-5218
|
| 65.
|
Juan, T. S.-C.,
Hailman, E.,
Kelley, M. J.,
Busse, L. A.,
Davy, E.,
Empig, C. J.,
Nahri, L. O.,
Wright, S. D.,
and Lichenstein, H. S.
(1996)
J. Biol. Chem.
270,
5219-5224
|
| 66.
|
Tobias, P. S.,
Soldau, K.,
Gegner, J. A.,
Mintz, D.,
and Ulevitch, R. J.
(1995)
J. Biol. Chem.
270,
10482-10488
|
| 67.
|
Tobias, P. S.,
Soldau, K.,
Iovine, N. M.,
Elsbach, P.,
and Weiss, J.
(1997)
J. Biol. Chem.
272,
18682-18685
|
| 68.
|
Gegner, J. A.,
Ulevitch, R. J.,
and Tobias, P. S.
(1995)
J. Biol. Chem.
270,
5320-5325
|
| 69.
|
Pikaar, J. C.,
Voorhout, W. F.,
van Golde, L. M.,
Verhoef, J.,
van Strijp, J. A. G.,
and van Iwaarden, J. F.
(1995)
J. Infect. Dis.
172,
481-489
|
| 70.
|
Griffis, J. M.,
Schneider, H.,
Mandrell, R. E.,
Yamasaki, R.,
Jarvis, A. G.,
Kim, J. J.,
Gibson, B. W.,
Hamadeh, R.,
and Apicella, M. A.
(1988)
Rev. Infect. Dis.
10 (suppl.),
S287-S295
|
| 71.
|
Borron, P.,
McIntosh, J. C.,
Korfhagen, T. R.,
Whitsett, J. A.,
Taylor, J.,
and Wright, J. R.
(2000)
Am. J. Physiol.
278,
L840-L847
|
| 72.
|
Elhalwagi, B. M.,
Damodarasamy, M.,
and McCormack, F. X.
(1997)
Biochemistry
36,
7018-7025
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike 